{"id":"https://openalex.org/W3092575360","doi":"https://doi.org/10.1002/onco.13566","title":"FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma","display_name":"FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma","publication_year":2020,"publication_date":"2020-10-12","ids":{"openalex":"https://openalex.org/W3092575360","doi":"https://doi.org/10.1002/onco.13566","mag":"3092575360","pmid":"https://pubmed.ncbi.nlm.nih.gov/33044793","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7930400"},"language":"en","primary_location":{"id":"doi:10.1002/onco.13566","doi":"https://doi.org/10.1002/onco.13566","is_oa":false,"landing_page_url":"https://doi.org/10.1002/onco.13566","pdf_url":null,"source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":"public-domain","license_id":"https://openalex.org/licenses/public-domain","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7930400","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076769955","display_name":"Abhilasha Nair","orcid":"https://orcid.org/0000-0002-4735-344X","observed_orcids":["https://orcid.org/0000-0002-4735-344X"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Abhilasha Nair","raw_affiliation_strings":["Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048562020","display_name":"Kelie M. Reece","orcid":"https://orcid.org/0000-0002-1011-4437","observed_orcids":["https://orcid.org/0000-0002-1011-4437"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kelie Reece","raw_affiliation_strings":["Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065105775","display_name":"Martha Boeri Donoghue","orcid":"https://orcid.org/0000-0003-4493-6399","observed_orcids":["https://orcid.org/0000-0003-4493-6399"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martha B. Donoghue","raw_affiliation_strings":["Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068800769","display_name":"Weishi Yuan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Weishi (Vivian) Yuan","raw_affiliation_strings":["Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003080414","display_name":"Lisa Rodr\u00edguez","orcid":"https://orcid.org/0000-0001-6417-0656","observed_orcids":["https://orcid.org/0000-0001-6417-0656"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa Rodriguez","raw_affiliation_strings":["Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077268765","display_name":"Patricia Keegan","orcid":"https://orcid.org/0000-0002-7266-395X","observed_orcids":["https://orcid.org/0000-0002-7266-395X"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patricia Keegan","raw_affiliation_strings":["Oncology Center for Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Center for Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5051520990","display_name":"Richard Pazdur","orcid":"https://orcid.org/0000-0002-4771-9923","observed_orcids":["https://orcid.org/0000-0002-4771-9923"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Pazdur","raw_affiliation_strings":["Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA","Oncology Center for Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]},{"raw_affiliation_string":"Oncology Center for Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5076769955"],"corresponding_institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"],"apc_list":{"value":1500,"currency":"USD","value_usd":1500},"apc_paid":null,"fwci":4.5306,"has_fulltext":false,"cited_by_count":94,"citation_normalized_percentile":{"value":0.96410229,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"26","issue":"3","first_page":"e484","last_page":"e491"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lenvatinib","display_name":"lenvatinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/hepatocellular-carcinoma","display_name":"hepatocellular carcinoma","score":0.9139999747276306},{"id":"https://openalex.org/keywords/unresectable-liver-cancer","display_name":"unresectable liver cancer","score":0.8640000224113464},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8009999990463257},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.8230000138282776},{"id":"https://openalex.org/keywords/reflect-trial","display_name":"REFLECT trial","score":0.984000027179718},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.9369999766349792},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9459999799728394},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9990000128746033},{"id":"https://openalex.org/keywords/mrecist","display_name":"mRECIST","score":0.7509999871253967},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.4620000123977661},{"id":"https://openalex.org/keywords/fda-drug-approval","display_name":"FDA drug approval","score":0.6110000014305115},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9079999923706055},{"id":"https://openalex.org/keywords/liver-metastases","display_name":"liver metastasis","score":0.5789999961853027},{"id":"https://openalex.org/keywords/proteinuria","display_name":"proteinuria","score":0.8619999885559082},{"id":"https://openalex.org/keywords/bleeding-events","display_name":"bleeding events","score":0.847000002861023},{"id":"https://openalex.org/keywords/hypothyroidism","display_name":"hypothyroidism","score":0.953000009059906},{"id":"https://openalex.org/keywords/palmar-plantar-erythrodysesthesia-syndrome","display_name":"palmar-plantar erythrodysesthesia syndrome","score":0.8650000095367432},{"id":"https://openalex.org/keywords/drug-efficacy-and-safety","display_name":"drug safety and efficacy","score":0.37400001287460327}],"concepts":[{"id":"https://openalex.org/C2776264508","wikidata":"https://www.wikidata.org/wiki/Q6523413","display_name":"Lenvatinib","level":4,"score":0.9758491516113281},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.7591902017593384},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7083436250686646},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5882270336151123},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5016186237335205},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.1423025131225586}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D006528","descriptor_name":"Carcinoma, Hepatocellular","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010671","descriptor_name":"Phenylurea Compounds","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1002/onco.13566","doi":"https://doi.org/10.1002/onco.13566","is_oa":false,"landing_page_url":"https://doi.org/10.1002/onco.13566","pdf_url":null,"source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":"public-domain","license_id":"https://openalex.org/licenses/public-domain","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7930400","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7930400","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"public-domain","license_id":"https://openalex.org/licenses/public-domain","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncologist","raw_type":"Text"},{"id":"pmid:33044793","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33044793","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The oncologist","raw_type":"Journal Article"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:7930400","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7930400","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"public-domain","license_id":"https://openalex.org/licenses/public-domain","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncologist","raw_type":"Text"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":6,"referenced_works":["https://openalex.org/W1971837077","https://openalex.org/W1994193851","https://openalex.org/W2145774014","https://openalex.org/W2158294624","https://openalex.org/W2891180940","https://openalex.org/W2969802526"],"related_works":["https://openalex.org/W2935887716","https://openalex.org/W4308877337","https://openalex.org/W2787358630","https://openalex.org/W3108370085","https://openalex.org/W3207337077","https://openalex.org/W3029141451","https://openalex.org/W2985556259","https://openalex.org/W7155559949","https://openalex.org/W2914296513","https://openalex.org/W3138601772"],"abstract_inverted_index":{"On":[0],"August":[1],"16,":[2],"2018,":[3],"the":[4,133,182,209,243,259,268],"U.S.":[5,244],"Food":[6,245],"and":[7,70,129,135,164,167,184,199,235,246,315],"Drug":[8,247],"Administration":[9],"approved":[10],"lenvatinib":[11,55,102,134,183,302],"(Lenvima,":[12],"Eisai":[13],"Inc.)":[14],"for":[15,61,76,111,178,267,291,299,338],"first-line":[16,269],"treatment":[17,270,337],"of":[18,127,162,171,250,261,271],"patients":[19,41,62,77,211,285,309,339],"with":[20,42,63,78,124,286,294,340],"unresectable":[21,47,272],"hepatocellular":[22,273],"carcinoma":[23,274],"(HCC).":[24,275],"Approval":[25],"was":[26,103,277],"based":[27],"on":[28],"an":[29,193,278,335],"international,":[30],"multicenter,":[31],"randomized,":[32],"open-label,":[33,279],"noninferiority":[34,280],"trial":[35,281],"(REFLECT;":[36],"NCT01761266)":[37],"conducted":[38],"in":[39,132,145,181,208,213],"954":[40,284],"previously":[43,341],"untreated":[44,342],"metastatic":[45],"or":[46,85,96,303],"HCC.":[48,343],"Patients":[49],"were":[50,190,216,289,327],"randomized":[51,283],"(1:1)":[52],"to":[53,109,159,301,318],"receive":[54],"(12":[56],"mg":[57,72,88],"orally":[58,73,89],"once":[59,74],"daily":[60,75],"a":[64,79,253,264],"baseline":[65,80],"body":[66,81],"weight":[67,82],"\u226560":[68],"kg":[69],"8":[71],"<60":[83],"kg)":[84],"sorafenib":[86,110,136,185],"(400":[87],"twice":[90],"daily)":[91],"until":[92],"radiological":[93],"disease":[94],"progression":[95,319],"unacceptable":[97],"toxicity.":[98],"REFLECT":[99,139,276,305],"demonstrated":[100,141,306],"that":[101,257,282,307],"noninferior":[104],"but":[105],"not":[106],"statistically":[107,142],"superior":[108],"overall":[112,168],"survival":[113,148],"(OS;":[114],"hazard":[115],"ratio,":[116],"[HR]":[117],"0.92;":[118],"95%":[119,152],"confidence":[120],"intervals":[121],"[CI],":[122],"0.79-1.06),":[123],"median":[125,160],"OS":[126],"13.6":[128],"12.3":[130],"months":[131,166],"arms,":[137,186],"respectively.":[138,187],"also":[140],"significant":[143],"improvements":[144],"investigator-assessed":[146],"progression-free":[147],"(PFS;":[149],"HR,":[150],"0.66;":[151],"CI,":[153],"0.57-0.77];":[154],"p":[155],"<":[156],"0.001),":[157],"corresponding":[158],"PFS":[161],"7.4":[163],"3.7":[165],"response":[169],"rate":[170],"24.1%":[172],"vs":[173],"9.2%":[174],"per":[175,197,200],"modified":[176],"RECIST":[177],"HCC":[179,287,300],"(mRECIST)":[180],"Consistent":[188],"results":[189],"observed":[191,207],"by":[192],"independent":[194],"review":[195,249],"facility":[196],"RECISTv1.1":[198],"mRECIST.":[201],"The":[202],"most":[203],"common":[204,329],"adverse":[205],"reactions":[206],"lenvatinib-treated":[210,308,331],"(\u226520%)":[212],"decreasing":[214],"frequency":[215],"hypertension,":[217],"fatigue,":[218],"diarrhea,":[219],"decreased":[220,223],"appetite,":[221],"arthralgia/myalgia,":[222],"weight,":[224],"abdominal":[225],"pain,":[226],"palmar-plantar":[227],"erythrodysesthesia":[228],"syndrome,":[229],"proteinuria,":[230],"dysphonia,":[231],"hemorrhagic":[232],"events,":[233],"hypothyroidism,":[234],"nausea.":[236],"IMPLICATIONS":[237],"FOR":[238],"PRACTICE:":[239],"This":[240],"article":[241],"describes":[242],"Administration's":[248],"data":[251],"from":[252],"single":[254,265],"trial,":[255],"REFLECT,":[256],"supported":[258],"approval":[260],"lenvatinib,":[262],"as":[263],"agent,":[266],"who":[288],"ineligible":[290],"liver-directed":[292],"therapy":[293,298],"no":[295],"prior":[296],"systemic":[297],"sorafenib.":[304,323],"had":[310],"similar":[311],"survival,":[312],"more":[313,328],"responses,":[314],"longer":[316],"time":[317],"than":[320],"those":[321],"receiving":[322],"Serious":[324],"side":[325],"effects":[326],"among":[330],"patients.":[332],"Lenvatinib":[333],"is":[334],"effective":[336]},"counts_by_year":[{"year":2026,"cited_by_count":14},{"year":2025,"cited_by_count":19},{"year":2024,"cited_by_count":24},{"year":2023,"cited_by_count":19},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":8}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2020-10-15T00:00:00"}